🔊 🔊 Important announcement 🔊 🔊 #PSOGI2025 #PSOGIBarcelona The #PSOGI2025 organizing committee is delighted to offer special packages to colleagues from Low income countries 💰 🇾🇪 🇸🇾 🇰🇵 🇹🇩 worldpopulationreview.com/country-rankin… Lower middle income countries 💰 💰 🇮🇳 🇧🇩 🇵🇰 🇲🇦 🇵🇭 🇳🇵 🇱🇰

El cáncer de apéndice, en sigilo, triplica su incidencia. antena3.com/noticias/salud…

This is really very clever science!!! sciencedirect.com/science/articl…

Congrats to all! ESMO - Eur. Oncology fostering the new generation of GI oncologists! #ESMOGI25 #ESMOAmbassadors

We start the 2nd day of #ESMOGI25 with a Multidisciplinary Tumour Board on Rectal Cancer! #ESMOAmbassadors

Amazing trip through translational research in colorectal cancer from Sanger sequencing to Single Cell by F. Di Nicolantonio at ESMO - Eur. Oncology #ESMOGI25 #ESMOAmbassadors

AI revolution coming to #ESMOGI25 Very interesting presentations from Prof Magali Svrcek and Jakob Nikolas Kather about the use and potential of #ArtificialIntelligence ESMO - Eur. Oncology #ESMOAmbassadors

Starting the 3rd day at #ESMOGI25 with a very interesting session showcasing selected publications of the ESMO - Eur. Oncology Gastrointestinal Oncology Journal chaired by Editors in Chief Prof. Irit Ben-Aharon & Prof Lordick #ESMOAmbassadors

Impressive review of the use of blood based assays for screening in Colorectal Cancer at #ESMOGI25 by Frank Sinicrope, MD Take a closer look at the takeaway points!! ESMO - Eur. Oncology #ESMOAmbassadors

A well thought approach to the management of anti-EGFR rash! A topical formulation of a BRAF inhibitor showing efficacy in a Phase II trial presented in the second proferred paper session at ESMO - Eur. Oncology #ESMOGI25 #ESMOAmbassadors

Interesting mini-Oral presentation from Dr Francesca Negri about the assessment of tumour immune microenvironment as a prognostic marker in Locally Advanced Rectal Cancer using a cohort from STAR-01 #ESMOGI25 ESMO - Eur. Oncology #ESMOAmbassadors

Thank you ESMO - Eur. Oncology #ESMOGI2025 chairs & organizing committee to bring GI #rarecancers to the stage and having me in good company. I hope I brought some awareness to #appendixcancers #pseudomyxoma #peritonealmesothelioma #ESMOAmbassadors Asociación Peritoneum Appendix Cancer PMP Research Foundation Hospital Universitario 12 de Octubre

🚨 New publication! Our review on the development journey of fruquintinib for metastatic colorectal cancer is now out. Proud to share this work with my co-authors! 🧬doi.org/10.1080/174604…

Proof of my previous statement 😊 Whole day meeting organising all #CommunicationStrategy for #ESMO25 Thanks to all the ESMO - Eur. Oncology #staff and all #CommunicationCommittee members who joined face2face/virtually Are you registered for #ESMO25? Do not miss it! #FOMO 😉

🔜 Te esperamos en ConVivir 2025: simposio de Vida y Tumores Digestivos. ✨ Si eres paciente o cuidador de una persona con un tumor digestivo, y estás interesado en el cuidado integral del paciente oncológico, este simposio es para ti. 👉 Organizado por Asociación de Tumores de Vías Biliares ACanPan

Agendado!! 🗓️25 Sept 2025 Quien más se apunta? “Vida y Tumores Digestivos” ConVivir 2025 ❤️ Asociación de Tumores de Vías Biliares ACanPan Asociación Peritoneum ACCGG2018

#PSOGI2025 #PSOGIBarcelona A 🔟 point guide to the congress 2️⃣ Why ❓ DO we DO what we do ❓ ❓ How do we EVOLVE ❓ psogicongress2025.com/programme-psog… Discover 👁️‍🗨️ some novel 🆕 and exciting sessions 🖲️ in the congress 🥌 Challening 🤼‍♀️ age old principles is essential to advance a

📷📷 Something rare is hiding inside… August is Appendix Cancer Awareness Month. Stay tuned to unwrap the facts, share the stories, and help us raise awareness of this often-overlooked cancer. #AppendixCancerAwareness #PseudomyxomaPeritonei #ZebrasNotHorses #RareButReal

Updated precemtabart tocentecan (M9140, CEACAM ADC) data in mCRC presented at ASCO '25: 31% response rate and mPFS of 6.9m in 100% irinotecan pretreated patients. ADCs can overcome TOP1 relative resistance. ascopubs.org/doi/10.1200/JC… #crcsm

How does #ESMOMCBS v2.0 reflect the evolving #oncology treatment landscape and the priorities of #PatientsWithCancer? Sjoukje Oosting shares her insights in the #ESMODailyReporter. 🔗 ow.ly/pLI450WBRNc